ICS-LABA

COMBINATION_PRODUCT2 trials

Sponsors

Incyte Corporation, AstraZeneca

Conditions

Eosinophilic AsthmaModerate to Severe Asthma

Phase 2

A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Inadequately Controlled Moderate to Severe Asthma

Active, not recruitingNCT05851443

Incyte CorporationModerate to Severe Asthma

Start: 2023-07-11End: 2027-07-05Updated: 2026-07-07

Phase 3

Randomised Clinical Trial to Investigate Efficacy and Safety of Benralizumab 30 mg SC as an add-on Therapy in Uncontrolled Eosinophilic Asthma Patients Treated With Medium-dose ICS-LABA Compared to Conventional Escalation to High-dose ICS-LABA Treatment

RecruitingNCT06750289

AstraZenecaEosinophilic Asthma

Start: 2025-03-28End: 2028-11-03Target: 400Updated: 2026-05-13